The IPI score in DLBCL, explained plainly | CION Cancer Clinics

The IPI, or International Prognostic Index, is a score from 0 to 5 that doctors use to sort diffuse large B-cell lymphoma (DLBCL) into risk groups. You get one point for each of five simple findings at diagnosis. A higher score means a higher chance, on average, that the lymphoma will be harder to control.

Why a score exists at all

DLBCL behaves very differently from one person to the next. Doctors needed a quick way to compare groups of patients in studies and to discuss risk in clinic. The IPI was built from the records of many patients, using findings that any hospital can check without special tests.

How your haematologist uses it

The score helps frame the conversation about how serious the lymphoma is. It can influence whether extra checks are done, such as looking at the spinal fluid, and whether a clinical trial is worth considering. It is one input among many, not a decision-maker on its own.

What it is not

It is not a countdown or a prediction for one person. It describes averages across large groups. People with a high score can do well, and people with a low score can have a hard course.

The IPI cannot tell you what will happen to you. It was designed to describe groups, and it leaves out much of what shapes a single person's course. Use it to understand the conversation, not to predict the outcome.

What it leaves out

The score says nothing about the lymphoma's biology. It does not include the GCB or non-GCB subtype, double hit gene changes, or how bulky a single mass is. It also ignores how quickly the lymphoma responds on the interim and end-of-treatment PET scans, which often tell your team far more.

Newer versions you may hear about

The R-IPI regroups the same factors for the rituximab era. The NCCN-IPI uses finer age bands, grades the LDH level, and counts only certain organs. Some reports quote a CNS-IPI, which estimates the risk of spread to the brain and spinal cord. Your team may use one or more of these.

Who the score fits least well

It fits less well for lymphoma that starts in the brain, in people with HIV, and in lymphoma that has transformed from a slower type. In those settings, ask your haematologist which risk measures they rely on instead.

Better questions to ask than "what is my score?"

Ask what the team is most concerned about in your case, and why. Ask which result would make them change the plan. Ask when the next scan is due and what a good response would look like on it. These answers are about you, and they will be far more useful to your family than a number from a chart.